GLAUKOS Corp (GKOS) FY2026 Q2 P&L / Income Statement

GLAUKOS Corp (GKOS) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net sales

185,610,000 US dollars

Cost of sales

34,016,000 US dollars

Gross profit

151,594,000 US dollars

Total operating expenses

168,861,000 US dollars

Loss from operations

negative 17,267,000 US dollars

Total non-operating (expense) income

negative 454,000 US dollars

Loss before taxes

negative 17,721,000 US dollars

Income tax provision

656,000 US dollars

Net loss

negative 18,377,000 US dollars

Corneal Health - UNITED STATES

28,190,000 US dollars

Corneal Health - International

2,240,000 US dollars

Glaucoma - UNITED STATES

118,549,000 US dollars

Glaucoma - International

36,631,000 US dollars

Acquired in-process research and development

1,500,000 US dollars

Research and development

51,301,000 US dollars

Selling, general and administrative

116,060,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.